Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reamberin for Metabolic Acidosis in Critically Ill Patients
NCT05147051Phase 2Completed
- Sponsor
- POLYSAN
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic acidosis comparing Reamberin group with Placebo group (2 arms). Primary endpoint: Elimination of acidosis at 24 hours. Started Jun 2021; status: completed.
02
Drugs
meglumine sodium succinate
03
Conditions
metabolic acidosis
Beyond the preview
Go deeper on NCT05147051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147051.